BRAF mutations in metastatic melanoma: a possible association with clinical outcome.

Abstract

Our results, besides confirming the high frequency of BRAF mutations in metastatic melanomas, also underline the potential importance of these mutations in disease outcome.

Keywords

ExonHazard ratioMelanomaMutationCancer researchGeneProportional hazards modelBiologySurvival analysisMedicineOncologyInternal medicineConfidence intervalGenetics

Affiliated Institutions

Karolinska Institutet SE

Related Publications

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

Bernhard Mlecnik , Marie Tosolini , Amos Kirilovsky +8 more

Purpose The prognosis of patients with colorectal cancer has sometimes proved uncertain; thus, the prognostic significance of immune criteria was compared with that of the tumor...

2011 Journal of Clinical Oncology 981 citations

Publication Info

Year: 2003
Type: article
Volume: 9
Issue: 9
Pages: 3362-8
Citations: 207
Access: Closed

External Links

Citation Metrics

207

OpenAlex

Cite This

APA Style

                            
                                    Rajiv Kumar, 
                                
                                    Sabrina Angelini, 
                                
                                    Kamila Czene
                                
                                et al.
                            
                            (2003). 
                            BRAF mutations in metastatic melanoma: a possible association with clinical outcome.. 
                            PubMed
                            , 9
                            (9)
                            , 3362-8.